

# Roberto Felice Caporali

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/637296/publications.pdf>

Version: 2024-02-01

282  
papers

13,952  
citations

20817

60  
h-index

27406

106  
g-index

286  
all docs

286  
docs citations

286  
times ranked

14380  
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term Outcome of Children Born to Women with Autoimmune Rheumatic Diseases: A Multicentre, Nationwide Study on 299 Randomly Selected Individuals. <i>Clinical Reviews in Allergy and Immunology</i> , 2022, 62, 346-353.	6.5	2
2	Myocardial involvement in anti-phospholipid syndrome: Beyond acute myocardial infarction. <i>Autoimmunity Reviews</i> , 2022, 21, 102990.	5.8	1
3	Ultrasound versus physical examination in predicting disease flare in children with juvenile idiopathic arthritis: a systematic literature review and qualitative synthesis. <i>Medical Ultrasonography</i> , 2022, , .	0.8	1
4	Pregnancy in juvenile idiopathic arthritis: maternal and foetal outcome, and impact on disease activity. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2210803.	2.7	4
5	Beyond Systemic Lupus Erythematosus and Anti-Phospholipid Syndrome: The Relevance of Complement From Pathogenesis to Pregnancy Outcome in Other Systemic Rheumatologic Diseases. <i>Frontiers in Pharmacology</i> , 2022, 13, 841785.	3.5	9
6	Controversies in rheumatology: ultrasound for monitoring of RA—do we need it?. <i>Rheumatology</i> , 2022, 61, 4245-4251.	1.9	3
7	Adherence of Italian rheumatologists to the EULAR recommendations and outcomes in early rheumatoid arthritis patients after starting conventional DMARDs: Methotrexate in Italian patients with Rheumatoid Arthritis (the MITRA study). A cohort study of the I. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.8	0
8	Retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: real-world results from the ASCORE study: an international 2-year observational study. <i>Clinical Rheumatology</i> , 2022, , 1.	2.2	7
9	Inflammatory correlates of the Patient Global Assessment of Disease Activity vary in relation to disease duration and autoantibody status in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1206-1213.	0.9	6
10	Lessons learned from the preclinical discovery and development of sarilumab for the treatment of rheumatoid arthritis. <i>Expert Opinion on Drug Discovery</i> , 2022, 17, 799-813.	5.0	3
11	What is the true incidence of COVID-19 in patients with rheumatic diseases?. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e18-e18.	0.9	89
12	Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA. <i>Joint Bone Spine</i> , 2021, 88, 105062.	1.6	14
13	Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 85-100.	3.0	14
14	Prevalence of COVID infections in a population of rheumatic patients from Lombardy and Marche treated with biological drugs or small molecules: A multicentre retrospective study. <i>Journal of Autoimmunity</i> , 2021, 116, 102545.	6.5	25
15	Telemedicine in rheumatology: a reliable approach beyond the pandemic. <i>Rheumatology</i> , 2021, 60, 366-370.	1.9	53
16	Ideal food pyramid for patients with rheumatoid arthritis: A narrative review. <i>Clinical Nutrition</i> , 2021, 40, 661-689.	5.0	24
17	The role of extracellular vesicles in rheumatoid arthritis: a systematic review. <i>Clinical Rheumatology</i> , 2021, 40, 3481-3497.	2.2	15
18	Clinical management of patients with rheumatoid arthritis during the COVID-19 pandemic. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 561-571.	3.0	10

#	ARTICLE	IF	CITATIONS
19	Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials. <i>Arthritis Research and Therapy</i> , 2021, 23, 119.	3.5	13
20	Ensuring tight control in patients with rheumatoid arthritis treated with targeted therapies during the COVID-19 pandemic using a telehealth strategy. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1243-1245.	0.9	5
21	Clinical pharmacology of filgotinib in the treatment of rheumatoid arthritis: current insights. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 661-670.	3.1	2
22	Long-term methotrexate use in rheumatoid arthritis patients: real-world data from the MARTE study. <i>Minerva Medica</i> , 2021, 112, 246-254.	0.9	2
23	Does methotrexate influence COVID-19 infection? Case series and mechanistic data. <i>Arthritis Research and Therapy</i> , 2021, 23, 166.	3.5	16
24	Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects. <i>RMD Open</i> , 2021, 7, e001637.	3.8	12
25	Instruments for Outcome Evaluation of Specific Domains in Primary Sjögren's Syndrome. <i>Biomolecules</i> , 2021, 11, 953.	4.0	1
26	Low Preconception Complement Levels Are Associated with Adverse Pregnancy Outcomes in a Multicenter Study of 260 Pregnancies in 197 Women with Antiphospholipid Syndrome or Carriers of Antiphospholipid Antibodies. <i>Biomedicines</i> , 2021, 9, 671.	3.2	17
27	Tofacitinib: Real-World Data and Treatment Persistence in Rheumatoid Arthritis. <i>Open Access Rheumatology: Research and Reviews</i> , 2021, Volume 13, 221-237.	1.6	9
28	The Crucial Questions on Synovial Biopsy: When, Why, Who, What, Where, and How?. <i>Frontiers in Medicine</i> , 2021, 8, 705382.	2.6	11
29	COVID-19 related poor mental health and sleep disorders in rheumatic patients: a citizen science project. <i>BMC Psychiatry</i> , 2021, 21, 385.	2.6	16
30	Association between age at disease onset of anti-neutrophil cytoplasmic antibody-associated vasculitis and clinical presentation and short-term outcomes. <i>Rheumatology</i> , 2021, 60, 617-628.	1.9	22
31	Methotrexate in Italian patients with Rheumatoid Arthritis (MITRA study): an observational study about the use of methotrexate in early RA patients and the adherence to the EULAR 2013 recommendations. A project of the Italian Society for Rheumatology. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 1077-1084.	0.8	1
32	The impact of disease extent and severity detected by quantitative ultrasound analysis in the diagnosis and outcome of giant cell arteritis. <i>Rheumatology</i> , 2020, 59, 2299-2307.	1.9	21
33	Modulating the wayward T cell: New horizons with immune checkpoint inhibitor treatments in autoimmunity, transplant, and cancer. <i>Journal of Autoimmunity</i> , 2020, 115, 102546.	6.5	13
34	Impact of COVID-19 outbreak in an Italian cohort of patients with systemic sclerosis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2095335.	2.7	11
35	Adherence to Mediterranean diet and patient perception of rheumatoid arthritis. <i>Complementary Therapies in Medicine</i> , 2020, 52, 102519.	2.7	11
36	Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1310-1319.	0.9	56

#	ARTICLE	IF	CITATIONS
37	Relevant non-pharmacologic topics for clinical research in rheumatic musculoskeletal diseases: The patient perspective. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 1305-1310.	1.9	8
38	New Rheumatoid Arthritis Treatments for “Old” Patients: Results of a Systematic Review. <i>Advances in Therapy</i> , 2020, 37, 3676-3691.	2.9	2
39	Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial. <i>Lancet</i> , The, 2020, 396, 267-276.	13.7	78
40	Epigenetics, pregnancy and autoimmune rheumatic diseases. <i>Autoimmunity Reviews</i> , 2020, 19, 102685.	5.8	16
41	Factors Predicting Early Failure of Etanercept in Rheumatoid Arthritis: An Analysis From the Gruppo Italiano di Studio sulla Early Arthritis (Italian Group for the Study of Early Arthritis) Registry. <i>Archives of Rheumatology</i> , 2020, 35, 163-169.	0.9	3
42	A Posteriori Dietary Patterns and Rheumatoid Arthritis Disease Activity: A Beneficial Role of Vegetable and Animal Unsaturated Fatty Acids. <i>Nutrients</i> , 2020, 12, 3856.	4.1	12
43	Occurrence of pulmonary embolism in a patient with mild clinical expression of COVID-19. <i>Thrombosis Research</i> , 2020, 192, 21-22.	1.7	13
44	Novel CORonaVirus Disease 2019 (COVID-19) epidemic: What are the risks for systemic sclerosis patients?. <i>Autoimmunity Reviews</i> , 2020, 19, 102558.	5.8	14
45	COVID-19 revisiting inflammatory pathways of arthritis. <i>Nature Reviews Rheumatology</i> , 2020, 16, 465-470.	8.0	149
46	Incidence of COVID-19 in Patients With Rheumatic Diseases Treated With Targeted Immunosuppressive Drugs: What Can We Learn From Observational Data?. <i>Arthritis and Rheumatology</i> , 2020, 72, 1600-1606.	5.6	95
47	Biologic therapy and spinal radiographic progression in patients with axial spondyloarthritis: A structured literature review. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2090604.	2.7	34
48	COVID-19 infection and rheumatoid arthritis: Faraway, so close!. <i>Autoimmunity Reviews</i> , 2020, 19, 102523.	5.8	353
49	Personalized medicine in rheumatoid arthritis: How immunogenicity impacts use of TNF inhibitors. <i>Autoimmunity Reviews</i> , 2020, 19, 102509.	5.8	13
50	Managing patients with rheumatic conditions during the covid-19 pandemic. <i>BMJ</i> , The, 2020, 369, m1633.	6.0	4
51	COVID-19 in systemic lupus erythematosus: Data from a survey on 417 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1150-1157.	3.4	52
52	What is the real role of ultrasound in the management of juvenile idiopathic arthritis?. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 437-439.	0.9	4
53	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 685-699.	0.9	1,860
54	Incidence and Clinical Course of COVID-19 in Patients with Connective Tissue Diseases: A Descriptive Observational Analysis. <i>Journal of Rheumatology</i> , 2020, 47, 1296-1296.	2.0	78

#	ARTICLE	IF	CITATIONS
55	Baricitinib for COVID-19: a suitable treatment?. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 1012-1013.	9.1	178
56	Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis. <i>Arthritis Research and Therapy</i> , 2020, 22, 290.	3.5	37
57	Retrospective evaluation of patient profiling and effectiveness of apremilast in an Italian multicentric cohort of psoriatic arthritis patients. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 19-26.	0.8	5
58	Thrombocytopenia in idiopathic inflammatory myopathies: a case series analysis. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 891-895.	0.8	2
59	Ultrasound assessment of lacrimal glands: a cross-sectional study in healthy subjects and a preliminary study in primary Sjögren's syndrome patients. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 126, 203-209.	0.8	0
60	The role of extra-corporeal membrane oxygenation (ECMO) in the treatment of diffuse alveolar haemorrhage secondary to ANCA-associated vasculitis: report of two cases and review of the literature. <i>Rheumatology International</i> , 2019, 39, 367-375.	3.0	26
61	Patients with rheumatoid arthritis facing sick leave or work disability meet varying regulations: a study among rheumatologists and patients from 44 European countries. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1472-1479.	0.9	7
62	Biosimilars vs originators: Are they the same?. <i>Autoimmunity Reviews</i> , 2019, 18, 102404.	5.8	6
63	An observational multicentre study on the efficacy and safety of assisted reproductive technologies in women with rheumatic diseases. <i>Rheumatology Advances in Practice</i> , 2019, 3, rkz005.	0.7	9
64	Tocilizumab Patterns of Use, Effectiveness, and Safety in Patients with Rheumatoid Arthritis: Final Results from a Set of Multi-National Non-Interventional Studies. <i>Rheumatology and Therapy</i> , 2019, 6, 231-243.	2.3	8
65	Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1553-1570.	5.6	75
66	FRIO042â€¦.CERTOLIZUMAB PEGOL EFFECTIVENESS IN WOMEN OF CHILDBEARING AGE WITH RHEUMATOID ARTHRITIS: RETROSPECTIVE ANALYSIS OF AN INTERNATIONAL MULTICENTRE COHORT. , 2019, , .		0
67	THU0290â€¦.DISEASE AND TREATMENT-RELATED MORBIDITY IN YOUNG AND ELDERLY PATIENTS WITH ANCA-ASSOCIATED VASCULITIS. , 2019, , .		0
68	FRIO145â€¦.FACTORS ASSOCIATED WITH NEAR REMISSION DIFFER BETWEEN AUTOANTIBODY-POSITIVE AND -NEGATIVE PATIENTS WITH EARLY RHEUMATOID ARTHRITIS TREATED WITH CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS. , 2019, , .		0
69	THU0164â€¦.THE DAS28 BASED ON THE ERYTHROCYTE SEDIMENTATION RATE MAY OVERESTIMATE DISEASE ACTIVITY IN EARLY, TREATMENT-NAÏVE PATIENTS WITH RHEUMATOID ARTHRITIS WITH HIGH LEVELS OF RHEUMATOID FACTOR. , 2019, , .		0
70	THU0079â€¦.AUTOANTIBODY-NEGATIVE PATIENTS, THE CUT-OFF OF SIX POINTS ACCORDING TO THE 2010 ACR/EULAR CRITERIA FOR RHEUMATOID ARTHRITIS MAY MISS A POPULATION OF SEVERE, PERSISTENT POLYARTHRITIS. , 2019, , .		0
71	AB0361â€¦.ASCORE, A 2-YEAR, OBSERVATIONAL, PROSPECTIVE MULTICENTRE STUDY OF SUBCUTANEOUS ABATACEPT FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN ROUTINE CLINICAL PRACTICE: 1-YEAR INTERIM ANALYSIS. , 2019, , .		1
72	Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course. <i>Journal of Clinical Medicine</i> , 2019, 8, 2013.	2.4	118

#	ARTICLE	IF	CITATIONS
73	Disease activity assessment of rheumatic diseases during pregnancy: a comprehensive review of indices used in clinical studies. <i>Autoimmunity Reviews</i> , 2019, 18, 164-176.	5.8	44
74	Subcutaneous tocilizumab alone or with a csDMARD in rheumatoid arthritis patients: subanalysis of Italian data from a multicenter phase IIIb/IV trial. <i>Clinical Rheumatology</i> , 2019, 38, 841-849.	2.2	5
75	“Disease knowledge index” and perspectives on reproductive issues: A nationwide study on 398 women with autoimmune rheumatic diseases. <i>Joint Bone Spine</i> , 2019, 86, 475-481.	1.6	25
76	Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis. <i>Rheumatology</i> , 2019, 58, 1056-1064.	1.9	8
77	Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis. <i>Autoimmunity Reviews</i> , 2019, 18, 93-106.	5.8	101
78	Aging in Primary Systemic Vasculitis: Implications for Diagnosis, Clinical Manifestations, and Management. <i>Drugs and Aging</i> , 2019, 36, 53-63.	2.7	10
79	Practical suggestions on intravenous iloprost in Raynaud’s phenomenon and digital ulcer secondary to systemic sclerosis: Systematic literature review and expert consensus. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 686-693.	3.4	34
80	Clinical implications of peripheral new bone formation in psoriatic arthritis: a literature-based review. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 310-317.	0.8	2
81	Real-world experience with tofacitinib for the treatment of rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 485-495.	0.8	20
82	Serum calprotectin as a marker of ultrasound-detected synovitis in early psoriatic and rheumatoid arthritis: results from a cross-sectional retrospective study. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 429-436.	0.8	6
83	Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries. <i>Rheumatology</i> , 2018, 57, 499-507.	1.9	32
84	Clinical characteristics and patient-reported outcomes in patients with inadequately controlled rheumatoid arthritis despite ongoing treatment. <i>RMD Open</i> , 2018, 4, e000615.	3.8	20
85	Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the <sc>LORHEN</sc> registry. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 422-430.	1.9	22
86	Prevalence of Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease in a cohort of patients treated with TNF-alpha inhibitors. <i>Modern Rheumatology</i> , 2018, 28, 542-549.	1.8	8
87	TNF inhibitors in rheumatoid arthritis and spondyloarthritis: Are they the same?. <i>Autoimmunity Reviews</i> , 2018, 17, 24-28.	5.8	39
88	Back to the future: forget ultrasound and focus on clinical assessment in rheumatoid arthritis management. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 18-20.	0.9	31
89	The Clinical Value of Autoantibodies in Rheumatoid Arthritis. <i>Frontiers in Medicine</i> , 2018, 5, 339.	2.6	64
90	20 years of experience with tumour necrosis factor inhibitors: what have we learned?. <i>Rheumatology</i> , 2018, 57, vii5-vii10.	1.9	34

#	ARTICLE	IF	CITATIONS
91	Tailored approach to rheumatoid arthritis treatment with TNF inhibitors: where do we stand?. <i>Rheumatology</i> , 2018, 57, vii1-vii4.	1.9	1
92	Randomized controlled trials and real-world data: differences and similarities to untangle literature data. <i>Rheumatology</i> , 2018, 57, vii54-vii58.	1.9	83
93	Switch or swap strategy in rheumatoid arthritis patients failing TNF inhibitors? Results of a modified Italian Expert Consensus. <i>Rheumatology</i> , 2018, 57, vii42-vii53.	1.9	24
94	Histopathology of the synovial tissue: perspectives for biomarker development in chronic inflammatory arthritides. <i>Reumatismo</i> , 2018, 70, 121-132.	0.9	7
95	The profiling of axial spondyloarthritis patient candidate to a biologic therapy: Consensus from a Delphi-panel of Italian experts. <i>Autoimmunity Reviews</i> , 2018, 17, 1251-1258.	5.8	2
96	Factors influencing use of biologic therapy and adoption of treat-to-target recommendations in current European rheumatology practice. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 2007-2014.	1.8	5
97	Unmet Needs in the Treatment of RA in the Era of Jak-i: IDRA (Italian Delphi Rheumatoid Arthritis) Consensus. <i>BioMed Research International</i> , 2018, 2018, 1-10.	1.9	3
98	Brief Report: Smoking in Systemic Sclerosis: A Longitudinal European Scleroderma Trials and Research Group Study. <i>Arthritis and Rheumatology</i> , 2018, 70, 1829-1834.	5.6	15
99	Comments on "Short-term reasons for withdrawal and adverse events associated with apremilast therapy for psoriasis in real-world practice compared with in clinical trials: A multicenter retrospective study". <i>Journal of the American Academy of Dermatology</i> , 2018, 79, e119-e120.	1.2	2
100	Serum Jo-1 Autoantibody and Isolated Arthritis in the Antisynthetase Syndrome: Review of the Literature and Report of the Experience of AENEAS Collaborative Group. <i>Clinical Reviews in Allergy and Immunology</i> , 2017, 52, 71-80.	6.5	60
101	Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry. <i>Clinical Rheumatology</i> , 2017, 36, 753-761.	2.2	28
102	Update of EULAR recommendations for the treatment of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1327-1339.	0.9	794
103	The management of first-line biologic therapy failures in rheumatoid arthritis: Current practice and future perspectives. <i>Autoimmunity Reviews</i> , 2017, 16, 1185-1195.	5.8	67
104	Undifferentiated connective tissue diseases and adverse pregnancy outcomes. An undervalued association?. <i>American Journal of Reproductive Immunology</i> , 2017, 78, e12762.	1.2	12
105	How I treat idiopathic patients with inflammatory myopathies in the clinical practice. <i>Autoimmunity Reviews</i> , 2017, 16, 999-1007.	5.8	22
106	What have multicentre registries across the world taught us about the disease features of systemic sclerosis?. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, 169-182.	1.7	18
107	In early inflammatory polyarthritis more intensive management according to the 2010 ACR/EULAR criteria leads to higher rates of clinical remission: comparison of two cohorts treated according to different treat-to-target protocols. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 401-405.	0.8	10
108	The role of ultrasound in the diagnosis and follow-up of large-vessel vasculitis: an update. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 103, 194-198.	0.8	11

#	ARTICLE	IF	CITATIONS
109	Recommendations for infectious disease screening in migrants to Western Europe with inflammatory arthropathies before starting biologic agents. Results from a multidisciplinary task force of four European societies (SIR, SER, SIMET, SEMTSI) facing the largest impact of the flow of migrants today. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 752-765.	0.8	16
110	Comparison of efficacy of first- versus second-line adalimumab in patients with rheumatoid arthritis: experience of the Italian biologics registries. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 660-665.	0.8	5
111	Patterns of tocilizumab use, effectiveness and safety in patients with rheumatoid arthritis: core data results from a set of multinational observational studies. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 899-906.	0.8	12
112	Tocilizumab in the treatment of patients with rheumatoid arthritis in real clinical practice: results of an Italian observational study. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 919-928.	0.8	2
113	Two-year retention rate of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: data from the LORHEN registry. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 804-809.	0.8	17
114	Spinal non-Hodgkinâ€™s lymphoma mimicking a flare of disease in a patient with ankylosing spondylitis treated with anti-TNF agents: case report and review of the literature. <i>Clinical Rheumatology</i> , 2016, 35, 275-280.	2.2	5
115	Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 103-109.	0.9	93
116	A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 163-169.	0.9	82
117	The impact of unrecognized autoimmune rheumatic diseases on the incidence of preeclampsia and fetal growth restriction: a longitudinal cohort study. <i>BMC Pregnancy and Childbirth</i> , 2016, 16, 313.	2.4	27
118	Cardiovascular Comorbidities Relate More than Others with Disease Activity in Rheumatoid Arthritis. <i>PLoS ONE</i> , 2016, 11, e0146991.	2.5	52
119	Undiagnosed connective tissue diseases. <i>Medicine (United States)</i> , 2016, 95, e4827.	1.0	15
120	Power Doppler ultrasonographic assessment of the joint-draining lymph node complex in rheumatoid arthritis: a prospective, proof-of-concept study on treatment with tumor necrosis factor inhibitors. <i>Arthritis Research and Therapy</i> , 2016, 18, 242.	3.5	13
121	Methotrexate and Rheumatoid Arthritis: Current Evidence Regarding Subcutaneous Versus Oral Routes of Administration. <i>Advances in Therapy</i> , 2016, 33, 369-378.	2.9	75
122	Drug survival of adalimumab in patients with rheumatoid arthritis over 10 years in the real-world settings: high rate remission together with normal function ability. <i>Clinical Rheumatology</i> , 2016, 35, 2649-2656.	2.2	19
123	Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2016, 18, 226.	3.5	87
124	Patient-reported impact of spondyloarthritis on work disability and working life: the ATLANTIS survey. <i>Arthritis Research and Therapy</i> , 2016, 18, 78.	3.5	52
125	Early, Incomplete, or Preclinical Autoimmune Systemic Rheumatic Diseases and Pregnancy Outcome. <i>Arthritis and Rheumatology</i> , 2016, 68, 2555-2562.	5.6	13
126	Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 382-389.	0.9	225



#	ARTICLE	IF	CITATIONS
127	Serum prealbumin is an independent predictor of mortality in systemic sclerosis outpatients. <i>Rheumatology</i> , 2016, 55, 315-319.	1.9	32
128	Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBcâ€‘positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study. <i>Journal of Rheumatology</i> , 2016, 43, 869-874.	2.0	49
129	Connective tissue diseases and autoimmune thyroid disorders in the first trimester of pregnancy. <i>Journal of Reproductive Immunology</i> , 2016, 114, 32-37.	1.9	19
130	Switching from Intravenous to Subcutaneous Formulation of Abatacept: Different Results in a Series of 21 Patients. <i>Journal of Rheumatology</i> , 2015, 42, 1993-1994.	2.0	5
131	Use of Ultrasoundâ€‘Guided Small Joint Biopsy to Evaluate the Histopathologic Response to Rheumatoid Arthritis Therapy: Recommendations for Application to Clinical Trials. <i>Arthritis and Rheumatology</i> , 2015, 67, 2601-2610.	5.6	39
132	Clinical Spectrum Time Course in Anti Jo-1 Positive Antisynthetase Syndrome. <i>Medicine (United States)</i> , 2015, 94, e1144.	1.0	133
133	Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs. <i>World Journal of Hepatology</i> , 2015, 7, 344.	2.0	61
134	Budget impact analysis of infliximab biosimilar: the Italian scenery. <i>Global &amp; Regional Health Technology Assessment</i> , 2015, 2, GRHTA.5000194.	0.1	6
135	The Draining Lymph Node in Rheumatoid Arthritis: Current Concepts and Research Perspectives. <i>BioMed Research International</i> , 2015, 2015, 1-10.	1.9	27
136	EULAR Sjogren's syndrome disease activity index (ESSDAI): a user guide. <i>RMD Open</i> , 2015, 1, e000022-e000022.	3.8	229
137	Soluble HLA-G in pregnancies complicated by autoimmune rheumatic diseases. <i>Journal of Reproductive Immunology</i> , 2015, 110, 67-73.	1.9	10
138	Fetal programming and systemic sclerosis. <i>American Journal of Obstetrics and Gynecology</i> , 2015, 213, 839.e1-839.e8.	1.3	7
139	Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1124-1131.	0.9	96
140	Oral Low-Dose Glucocorticoids Should Be Included in Any Recommendation for the Use of Non-Biologic and Biologic Disease-Modifying Antirheumatic Drugs in the Treatment of Rheumatoid Arthritis. <i>NeuroImmunoModulation</i> , 2015, 22, 104-111.	1.8	12
141	Systemic vasculitis and pregnancy: A multicenter study on maternal and neonatal outcome of 65 prospectively followed pregnancies. <i>Autoimmunity Reviews</i> , 2015, 14, 686-691.	5.8	46
142	Rheumatoid arthritis treatment: the earlier the better to prevent joint damage. <i>RMD Open</i> , 2015, 1, e000057.	3.8	98
143	A comparison between nailfold capillaroscopy patterns in adulthood in juvenile and adult-onset systemic sclerosis: A EUSTAR exploratory study. <i>Microvascular Research</i> , 2015, 102, 19-24.	2.5	13
144	Validation of EULAR primary SjÃ¶gren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 859-866.	0.9	193

#	ARTICLE	IF	CITATIONS
145	Prospectively-followed pregnancies in patients with inflammatory arthritis taking biological drugs: an Italian multicentre study. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 688-93.	0.8	18
146	Disease-related malnutrition in systemic sclerosis: evidences and implications. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S190-4.	0.8	8
147	Biotechnological Drugs: The Breakthrough in Autoimmune Rheumatic Conditions. <i>BioMed Research International</i> , 2014, 2014, 1-2.	1.9	0
148	Perivascular fibrosis and IgG4-related disease: a case report. <i>Reumatismo</i> , 2014, 66, 245-248.	0.9	2
149	Treatment Comparison in Rheumatoid Arthritis: Head-to-Head Trials and Innovative Study Designs. <i>BioMed Research International</i> , 2014, 2014, 1-17.	1.9	25
150	Effects of Anti-TNF Alpha Drugs on Disability in Patients with Rheumatoid Arthritis: Long-Term Real-Life Data from the Lorhen Registry. <i>BioMed Research International</i> , 2014, 2014, 1-8.	1.9	8
151	B Cells in Rheumatoid Arthritis: From Pathogenic Players to Disease Biomarkers. <i>BioMed Research International</i> , 2014, 2014, 1-14.	1.9	121
152	The Role of Tumour Necrosis Factor in the Pathogenesis of Immune-Mediated Diseases. <i>International Journal of Immunopathology and Pharmacology</i> , 2014, 27, 1-10.	2.1	69
153	Adalimumab in the Treatment of Immune-Mediated Diseases. <i>International Journal of Immunopathology and Pharmacology</i> , 2014, 27, 33-48.	2.1	65
154	Anti-TNF Agents as Therapeutic Choice in Immune-Mediated Inflammatory Diseases: Focus on Adalimumab. <i>International Journal of Immunopathology and Pharmacology</i> , 2014, 27, 11-32.	2.1	50
155	Pneumocephalus due to granulomatosis with polyangiitis. <i>Rheumatology</i> , 2014, 53, 2269-2269.	1.9	2
156	Biosimilars: lights and shadows in rheumatology. <i>Rheumatology Reports</i> , 2014, 6, .	0.1	1
157	Critical role of water in the direct oxidation of CO and hydrocarbons in diesel exhaust after treatment catalysis. <i>Applied Catalysis B: Environmental</i> , 2014, 147, 764-769.	20.2	42
158	High expression levels of the B cell chemoattractant CXCL13 in rheumatoid synovium are a marker of severe disease. <i>Rheumatology</i> , 2014, 53, 1886-1895.	1.9	63
159	The 158V V Fc gamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 716-721.	0.9	52
160	Modulating the co-stimulatory signal for T cell activation in rheumatoid arthritis: Could it be the first step of the treatment?. <i>Autoimmunity Reviews</i> , 2014, 13, 49-53.	5.8	28
161	Disease-related nutritional risk and mortality in systemic sclerosis. <i>Clinical Nutrition</i> , 2014, 33, 558-561.	5.0	19
162	Predictors of response to anti-TNF therapy in RA patients with moderate or high DAS28 scores. <i>Joint Bone Spine</i> , 2014, 81, 37-40.	1.6	23

#	ARTICLE	IF	CITATIONS
163	Treating rheumatoid arthritis to target: an Italian rheumatologists' survey on the acceptance of the treat-to-target recommendations. <i>Clinical and Experimental Rheumatology</i> , 2014, 32, 471-6.	0.8	14
164	Therapeutic Options in Anti-Jo1 Antisynthetase Syndrome With Interstitial Lung Disease: Comment on the Article by Marie et al. <i>Arthritis Care and Research</i> , 2013, 65, 1548-1548.	3.4	3
165	Glucocorticoids in Rheumatoid Arthritis. <i>Drugs</i> , 2013, 73, 31-43.	10.9	18
166	Long-term safety of abatacept in patients with rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2013, 12, 1115-1117.	5.8	30
167	The TTTT B lymphocyte stimulator promoter haplotype is associated with good response to rituximab therapy in seropositive rheumatoid arthritis resistant to tumor necrosis factor blockers. <i>Arthritis and Rheumatism</i> , 2013, 65, 88-97.	6.7	22
168	Cyclosporine in Anti-Jo1-positive Patients with Corticosteroid-refractory Interstitial Lung Disease. <i>Journal of Rheumatology</i> , 2013, 40, 484-492.	2.0	82
169	Overuse of Prescription and OTC Non-Steroidal Anti-Inflammatory Drugs in Patients with Rheumatoid Arthritis and Osteoarthritis. <i>International Journal of Immunopathology and Pharmacology</i> , 2013, 26, 279-281.	2.1	21
170	Stress Doppler Echocardiography in Systemic Sclerosis: Evidence for a Role in the Prediction of Pulmonary Hypertension. <i>Arthritis and Rheumatism</i> , 2013, 65, 2403-2411.	6.7	50
171	In patients with early rheumatoid arthritis, the new ACR/EULAR definition of remission identifies patients with persistent absence of functional disability and suppression of ultrasonographic synovitis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 245-249.	0.9	80
172	Chromosomally integrated human herpesvirus 6 in a patient with systemic lupus erythematosus. <i>Lupus</i> , 2013, 22, 1087-1088.	1.6	1
173	Very early rheumatoid arthritis as a predictor of remission: a multicentre real life prospective study. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 858-862.	0.9	112
174	The Multifaceted Aspects of Interstitial Lung Disease in Rheumatoid Arthritis. <i>BioMed Research International</i> , 2013, 2013, 1-13.	1.9	82
175	Diffuse alveolar hemorrhage as a manifestation of Behçet disease. <i>Reumatismo</i> , 2013, 65, 138-41.	0.9	1
176	Performance of the 2010 Classification Criteria for Rheumatoid Arthritis: A Systematic Literature Review and a Meta-Analysis. <i>PLoS ONE</i> , 2013, 8, e56528.	2.5	18
177	Drug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and seronegative spondyloarthritis: analysis from the MonitorNet database. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, 857-63.	0.8	32
178	The role of low-dose glucocorticoids for rheumatoid arthritis in the biologic era. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, S9-13.	0.8	15
179	Atherosclerosis and Rheumatoid Arthritis: More Than a Simple Association. <i>Mediators of Inflammation</i> , 2012, 2012, 1-8.	3.0	49
180	Assessment of synovitis to predict bone erosions in rheumatoid arthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2012, 4, 235-244.	2.7	25

#	ARTICLE	IF	CITATIONS
181	Prevalence and significance of previously undiagnosed rheumatic diseases in pregnancy. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 918-923.	0.9	36
182	Evidence for caveolin-1 as a new susceptibility gene regulating tissue fibrosis in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1034-1041.	0.9	33
183	Primary anti-phospholipid syndrome: any role for serum complement levels in predicting pregnancy complications?. <i>Rheumatology</i> , 2012, 51, 2186-2190.	1.9	35
184	Disease-related malnutrition in outpatients with systemic sclerosis. <i>Clinical Nutrition</i> , 2012, 31, 666-671.	5.0	50
185	Inflammatory lesions in the bone marrow of rheumatoid arthritis patients: a morphological perspective. <i>Arthritis Research and Therapy</i> , 2012, 14, 229.	3.5	43
186	Uterine artery Doppler velocimetry and obstetric outcomes in connective tissue diseases diagnosed during the first trimester of pregnancy. <i>Prenatal Diagnosis</i> , 2012, 32, 1094-1101.	2.3	11
187	Serum levels of CXCL13 are associated with ultrasonographic synovitis and predict power doppler persistence in early rheumatoid arthritis treated with non-biological disease-modifying antirheumatic drugs. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A12.3-A13.	0.9	0
188	Ultrasonographic and MRI characterisation of the palindromic phase of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 625-626.	0.9	18
189	Low-dose oral prednisone improves clinical and ultrasonographic remission rates in early rheumatoid arthritis. Results of a 12 month open-label randomized study.. <i>Arthritis Research and Therapy</i> , 2012, 14, R112.	3.5	59
190	Serum levels of CXCL13 are associated with ultrasonographic synovitis and predict power Doppler persistence in early rheumatoid arthritis treated with non-biological disease-modifying anti-rheumatic drugs. <i>Arthritis Research and Therapy</i> , 2012, 14, R34.	3.5	47
191	Brief Report: Successful pregnancies but a higher risk of preterm births in patients with systemic sclerosis: An Italian multicenter study. <i>Arthritis and Rheumatism</i> , 2012, 64, 1970-1977.	6.7	134
192	Early treatment in early undifferentiated arthritis. <i>Autoimmunity Reviews</i> , 2012, 11, 589-592.	5.8	31
193	Current Considerations for the Treatment of Severe Chronic Pain: The Potential for Tapentadol. <i>Pain Practice</i> , 2012, 12, 290-306.	1.9	35
194	Biomarkers and prognostic stratification in psoriatic arthritis. <i>Reumatismo</i> , 2012, 64, 88-98.	0.9	7
195	Predicting and managing the progression of structural damage in rheumatoid arthritis: where do we stand?. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, 459-63.	0.8	4
196	Inappropriate exercise-induced increase in pulmonary artery pressure in patients with systemic sclerosis. <i>Heart</i> , 2011, 97, 112-117.	2.9	74
197	Systemic sclerosis in aquaporin-4 antibody-positive longitudinally extensive transverse myelitis. <i>Journal of the Neurological Sciences</i> , 2011, 303, 139-141.	0.6	21
198	Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 476-481.	0.9	330

#	ARTICLE	IF	CITATIONS
199	Definition of remission and relapse in polymyalgia rheumatica: data from a literature search compared with a Delphi-based expert consensus. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 447-453.	0.9	81
200	Switching rheumatoid arthritis treatments: An update. <i>Autoimmunity Reviews</i> , 2011, 10, 397-403.	5.8	33
201	Rheumatoid arthritis and renal light-chain deposition disease: long-term effectiveness of TNF- $\alpha$ blockade with etanercept. <i>International Urology and Nephrology</i> , 2011, 43, 909-912.	1.4	0
202	Pregnancy Outcomes in Patients with Autoimmune Diseases and Anti-Ro/SSA Antibodies. <i>Clinical Reviews in Allergy and Immunology</i> , 2011, 40, 27-41.	6.5	155
203	The correct prednisone starting dose in polymyalgia rheumatica is related to body weight but not to disease severity. <i>BMC Musculoskeletal Disorders</i> , 2011, 12, 94.	1.9	34
204	Sinonasal surgery in Wegener's granulomatosis: Is it time to go on?. <i>Laryngoscope</i> , 2011, 121, 2717-2718.	2.0	2
205	Pulmonary arterial hypertension in antisynthetase syndrome: Comment on the article by Chatterjee and Farver. <i>Arthritis Care and Research</i> , 2011, 63, 633-634.	3.4	16
206	B cell distribution and activation-induced cytidine deaminase expression in rheumatoid synovitis: clinical and bio-molecular correlates. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, A55-A55.	0.9	3
207	Subclinical remodelling of draining lymph node structure in early and established rheumatoid arthritis assessed by power Doppler ultrasonography. <i>Rheumatology</i> , 2011, 50, 1395-1400.	1.9	36
208	Updating the Italian Society for Rheumatology recommendations for biologic therapy in adult patients with inflammatory rheumatic diseases. <i>Clinical and Experimental Rheumatology</i> , 2011, 29, S3-6.	0.8	2
209	Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology I. Efficacy. <i>Clinical and Experimental Rheumatology</i> , 2011, 29, S7-14.	0.8	23
210	Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology II. Safety. <i>Clinical and Experimental Rheumatology</i> , 2011, 29, S15-27.	0.8	31
211	Efficacy and Safety of Anti-Tumour Necrosis Factor in Elderly Patients with Rheumatoid Arthritis: An Observational Study. <i>Clinical Reviews in Allergy and Immunology</i> , 2010, 38, 90-96.	6.5	63
212	Tumour necrosis factor antagonist therapy and cancer development: Analysis of the LORHEN registry. <i>Autoimmunity Reviews</i> , 2010, 9, 175-180.	5.8	80
213	Switching TNF-alpha antagonists in rheumatoid arthritis: The experience of the LORHEN registry. <i>Autoimmunity Reviews</i> , 2010, 9, 465-469.	5.8	38
214	The effect of pharmacological therapy on the cardiovascular system of patients with systemic rheumatic diseases. <i>Autoimmunity Reviews</i> , 2010, 9, 835-839.	5.8	75
215	Safety of tumor necrosis factor $\alpha$ blockers in hepatitis B virus occult carriers (hepatitis B surface) Tj ETQq1 1 0.784314 rgBT /Overlock Research, 2010, 62, 749-754.	3.4	110
216	Early disease control by low-dose prednisone comedication may affect the quality of remission in patients with early rheumatoid arthritis. <i>Annals of the New York Academy of Sciences</i> , 2010, 1193, 139-145.	3.8	38

#	ARTICLE	IF	CITATIONS
217	Characteristics of Joint Involvement and Relationships with Systemic Inflammation in Systemic Sclerosis: Results from the EULAR Scleroderma Trial and Research Group (EUSTAR) Database. <i>Journal of Rheumatology</i> , 2010, 37, 1488-1501.	2.0	161
218	Anticyclic Citrullinated Peptide Antibodies as Markers of Erosive Arthritis in Antisynthetase Syndrome: Table 1.. <i>Journal of Rheumatology</i> , 2010, 37, 1967.2-1967.	2.0	27
219	Safety of Mud-Bath Applications in Moderately Active Rheumatoid Arthritis. <i>Journal of Musculoskeletal Pain</i> , 2010, 18, 81-87.	0.3	5
220	Comparison of Brain Natriuretic Peptide (BNP) and NT-proBNP in Screening for Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2010, 37, 2064-2070.	2.0	68
221	Ultrasonographic evaluation of joint involvement in early rheumatoid arthritis in clinical remission: power Doppler signal predicts short-term relapse. <i>Rheumatology</i> , 2009, 48, 1092-1097.	1.9	274
222	TNF- $\alpha$ Antagonist Survival Rate in a Cohort of Rheumatoid Arthritis Patients Observed under Conditions of Standard Clinical Practice. <i>Annals of the New York Academy of Sciences</i> , 2009, 1173, 837-846.	3.8	130
223	Anti-TNF- $\alpha$ therapy in a cohort of rheumatoid arthritis patients: Clinical outcomes. <i>Autoimmunity Reviews</i> , 2009, 8, 260-265.	5.8	35
224	Serious infections during anti-TNF- $\alpha$ treatment in rheumatoid arthritis patients. <i>Autoimmunity Reviews</i> , 2009, 8, 266-273.	5.8	148
225	Treatment of rheumatoid arthritis with anti-TNF-alpha agents: A reappraisal. <i>Autoimmunity Reviews</i> , 2009, 8, 274-280.	5.8	101
226	Predicting response to anti-TNF treatment in rheumatoid arthritis patients. <i>Autoimmunity Reviews</i> , 2009, 8, 431-437.	5.8	50
227	Long term treatment of rheumatoid arthritis with rituximab. <i>Autoimmunity Reviews</i> , 2009, 8, 591-594.	5.8	37
228	Pain and rheumatology: An overview of the problem. <i>European Journal of Pain Supplements</i> , 2009, 3, 105-109.	0.0	9
229	Pain in arthritis. <i>European Journal of Pain Supplements</i> , 2009, 3, 123-127.	0.0	6
230	Efficacy and Safety of Anti-TNF- $\alpha$ Therapy Combined with Cyclosporine a in Patients with Rheumatoid Arthritis and Concomitant Hepatitis C Virus Infection. <i>International Journal of Immunopathology and Pharmacology</i> , 2009, 22, 543-546.	2.1	21
231	Prevalence of undiagnosed autoimmune rheumatic diseases in the first trimester of pregnancy. Results of a two-steps strategy using a self-administered questionnaire and autoantibody testing. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2008, 115, 51-57.	2.3	22
232	Prescribing pattern of drugs in the treatment of osteoarthritis in italian general practice: The effect of rofecoxib withdrawal. <i>Arthritis and Rheumatism</i> , 2008, 59, 568-574.	6.7	36
233	Safety and usefulness of minor salivary gland biopsy: Retrospective analysis of 502 procedures performed at a single center. <i>Arthritis and Rheumatism</i> , 2008, 59, 714-720.	6.7	100
234	Mature antigen-experienced T helper cells synthesize and secrete the B cell chemoattractant CXCL13 in the inflammatory environment of the rheumatoid joint. <i>Arthritis and Rheumatism</i> , 2008, 58, 3377-3387.	6.7	124

#	ARTICLE	IF	CITATIONS
235	The effect of newly diagnosed undifferentiated connective tissue disease on pregnancy outcome. American Journal of Obstetrics and Gynecology, 2008, 199, 632.e1-632.e6.	1.3	23
236	DMARDS and infections in rheumatoid arthritis. Autoimmunity Reviews, 2008, 8, 139-143.	5.8	70
237	Treatment of rheumatic diseases in patients with HCV and HIV infection. Autoimmunity Reviews, 2008, 8, 100-103.	5.8	29
238	Anti-cyclic citrullinated peptide antibodies in primary Sjogren's syndrome may be associated with non-erosive synovitis. Arthritis Research and Therapy, 2008, 10, R51.	3.5	64
239	Chapter 23 Glucocorticoid Therapy for Polymyalgia Rheumatica. Handbook of Systemic Autoimmune Diseases, 2008, 9, 257-263.	0.1	0
240	Characterization of immunoglobulin variable regions of two human pathogenic monoclonal cryocryoglobulins. Molecular Immunology, 2008, 45, 1519-1524.	2.2	2
241	What can we learn from treatment-induced changes in rheumatoid factor and anti-citrullinated Peptide antibodies?. Journal of Rheumatology, 2008, 35, 1903-5.	2.0	10
242	High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor $\alpha$ inhibitors in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2007, 66, 302-307.	0.9	114
243	Comment on: parotid gland biopsy compared with labial biopsy in the diagnosis of patients with primary Sjogren's Syndrome. Rheumatology, 2007, 46, 1625-1625.	1.9	8
244	CCL21 Expression Pattern of Human Secondary Lymphoid Organ Stroma Is Conserved in Inflammatory Lesions with Lymphoid Neogenesis. American Journal of Pathology, 2007, 171, 1549-1562.	3.8	94
245	Clinical features of ANCA $\alpha$ positive systemic lupus erythematosus: report of two cases. Scandinavian Journal of Rheumatology, 2007, 36, 74-76.	1.1	5
246	Immunohistological assessment of the synovial tissue in small joints in rheumatoid arthritis: validation of a minimally invasive ultrasound-guided synovial biopsy procedure. Arthritis Research and Therapy, 2007, 9, R101.	3.5	63
247	B cells in rheumatoid arthritis. Autoimmunity Reviews, 2007, 6, 482-487.	5.8	39
248	B cells in rheumatoid arthritis. Autoimmunity Reviews, 2007, 7, 137-142.	5.8	70
249	Predictive Value of Antibodies to Citrullinated Peptides and Rheumatoid Factors in Anti $\alpha$ TNF $\alpha$ Treated Patients. Annals of the New York Academy of Sciences, 2007, 1109, 287-295.	3.8	35
250	Clinical and electrophysiological evaluation of peripheral neuropathy in rheumatoid arthritis. Journal of the Peripheral Nervous System, 2006, 11, 174-175.	3.1	20
251	Glucocorticoid Effects on Adrenal Steroids and Cytokine Responsiveness in Polymyalgia Rheumatica and Elderly Onset Rheumatoid Arthritis. Annals of the New York Academy of Sciences, 2006, 1069, 307-314.	3.8	10
252	Is the Course of Steroid-Treated Polymyalgia Rheumatica More Severe in Women?. Annals of the New York Academy of Sciences, 2006, 1069, 315-321.	3.8	33

#	ARTICLE	IF	CITATIONS
253	Osteoarthritis: An Overview of the Disease and Its Treatment Strategies. <i>Seminars in Arthritis and Rheumatism</i> , 2005, 35, 1-10.	3.4	316
254	The Characteristics of Symptomatic Osteoarthritis in General and Specialist Practice in Italy: Design and Methods of the AMICA Study. <i>Seminars in Arthritis and Rheumatism</i> , 2005, 35, 11-16.	3.4	5
255	Clinical Presentation of Osteoarthritis in General Practice: Determinants of Pain in Italian Patients in the AMICA Study. <i>Seminars in Arthritis and Rheumatism</i> , 2005, 35, 17-23.	3.4	53
256	Analysis of Pharmacologic and Nonpharmacologic Prescription Patterns of General Practitioners and Specialists in the AMICA Study. <i>Seminars in Arthritis and Rheumatism</i> , 2005, 35, 24-30.	3.4	11
257	Comorbid Conditions in the AMICA Study Patients: Effects on the Quality of Life and Drug Prescriptions by General Practitioners and Specialists. <i>Seminars in Arthritis and Rheumatism</i> , 2005, 35, 31-37.	3.4	64
258	Do Physicians Treat Symptomatic Osteoarthritis Patients Properly? Results of the AMICA Experience. <i>Seminars in Arthritis and Rheumatism</i> , 2005, 35, 38-42.	3.4	35
259	Systematic microanatomical analysis of CXCL13 and CCL21 in situ production and progressive lymphoid organization in rheumatoid synovitis. <i>European Journal of Immunology</i> , 2005, 35, 1347-1359.	2.9	232
260	Involvement of subchondral bone marrow in rheumatoid arthritis: Lymphoid neogenesis and in situ relationship to subchondral bone marrow osteoclast recruitment. <i>Arthritis and Rheumatism</i> , 2005, 52, 3448-3459.	6.7	93
261	Cardiovascular effects of coxibs. <i>Lupus</i> , 2005, 14, 785-788.	1.6	12
262	Analysis of the apolipoprotein(a) size polymorphism in patients with systemic lupus erythematosus. <i>International Journal of Molecular Medicine</i> , 2005, 15, 661.	4.0	1
263	Autoantibodies to heterogeneous nuclear ribonucleoproteins. <i>Autoimmunity</i> , 2005, 38, 25-32.	2.6	31
264	Multilevel examination of minor salivary gland biopsy for Sjogren's syndrome significantly improves diagnostic performance of AECG classification criteria. <i>Arthritis Research</i> , 2005, 7, R343.	2.0	46
265	Rheumatoid arthritis in beta-thalassemic trait: clinical, serologic and immunogenetic profile. <i>Joint Bone Spine</i> , 2004, 71, 117-120.	1.6	9
266	Inflammatory myopathy in a patient with cutaneous findings of pityriasis rubra pilaris: a case of Wong's dermatomyositis. <i>Clinical Rheumatology</i> , 2004, 23, 63-65.	2.2	15
267	Polyarthrite rhumatoïde associée à un trait bêta-thalassémique : aspect clinique, sérologique et immunogénétique. <i>Revue Du Rhumatisme (Edition Française)</i> , 2004, 71, 203-207.	0.0	0
268	Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. <i>Arthritis Research</i> , 2004, 6, R264-72.	2.0	140
269	Prednisone plus Methotrexate for Polymyalgia Rheumatica. <i>Annals of Internal Medicine</i> , 2004, 141, 493.	3.9	204
270	Shrinking lung syndrome in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2003, 48, 2999-3000.	6.7	20



#	ARTICLE	IF	CITATIONS
271	Presenting features of polymyalgia rheumatica (PMR) and rheumatoid arthritis with PMR-like onset: a prospective study. <i>Annals of the Rheumatic Diseases</i> , 2001, 60, 1021-1024.	0.9	114
272	Identification of autoantibodies to the I protein of the heterogeneous nuclear ribonucleoprotein complex in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1996, 39, 1669-1676.	6.7	26
273	Iron status in Still's disease. <i>Lancet, The</i> , 1995, 345, 58-59.	13.7	6
274	Allopurinol mouthwashes in methotrexate-induced stomatitis. <i>Arthritis and Rheumatism</i> , 1994, 37, 777-778.	6.7	12
275	Anticardiolipin antibodies in children and adolescents with insulin-dependent diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , 1994, 23, 63-64.	2.8	0
276	Antiphospholipid antibodies in children with idiopathic cerebral ischaemia. <i>Lancet, The</i> , 1994, 344, 1232.	13.7	9
277	Autoantibody profile in thrombotic thrombocytopenic purpura. <i>Transfusion Science</i> , 1992, 13, 33-36.	0.6	2
278	Antibodies from patients with rheumatoid arthritis and systemic lupus erythematosus recognize different epitopes of a single heterogeneous nuclear rnp core protein. <i>Arthritis and Rheumatism</i> , 1990, 33, 180-186.	6.7	42
279	Antibodies to hnRNP core protein A1 in connective tissue diseases. <i>Journal of Cellular Biochemistry</i> , 1989, 40, 43-47.	2.6	27
280	Adherence of Italian rheumatologists to the EULAR recommendations and outcomes in early rheumatoid arthritis patients after starting conventional DMARDs: Methotrexate in Italian patients with Rheumatoid Arthritis (the MITRA study). A cohort study of the I. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.8	0
281	Subcutaneously-Administered Infliximab in the Management of Rheumatoid Arthritis: A Short Narrative Review of Current Clinical Evidence. <i>Journal of Inflammation Research</i> , 0, Volume 15, 3259-3267.	3.5	0
282	Immunosuppressant Treatment in Rheumatic Musculoskeletal Diseases Does Not Inhibit Elicitation of Humoral Response to SARS-CoV-2 Infection and Preserves Effector Immune Cell Populations. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	0